Donate

Donating to clinical trials enables real benefit to be realised by real people — including immediate benefit for the people who take part. Any donation, no matter what size, will help us to conduct our clinical trials and lead to better health outcomes for the 33,200 Australian patients diagnosed with GI cancer each year.

Or you can pledge your support as a regular giving partner, providing the financial stability that allows us to plan for the future.

Donations over $2.00 are tax-deductible. A tax receipt will be issued on receipt of your donation.

Donate Online

To make a one-off donation or to set up a regular donation using your credit card, please click here.

Direct Deposit

To make a direct deposit donation using your bank account, please click here.
You will then receive a confirmation email with your unique reference details to make a direct deposit donation.

Over the phone donations

Please call us on 1300 666 769, during business hours (Monday to Friday, 9am to 5pm).

Donate via email

Please contact us via email to donations@gicancer.org.au. Be sure to include your name and contact details as well as your payment details.

Fundraise

Please contact us via email to donations

Contact melanie@gicancer.org.au if you are interested in fundraising for GI Cancer research. You can take on a Gutsy Challenge or set up a Community Fundraiser. Either way we are here to help so please contact us to find out more

We can also help you if you are looking to set up the following;

In Memory gift or fundraising page – click here for more,
a bequest in your Will – click here for more, or
Workplace giving – click here for more.

Clinical trials: real people, real benefits

GI Cancer Institute clinical trials are about bringing real benefit to real people — including immediate benefit for the people who take part.

Since 1991, our trials have helped save and extend lives, and improve the quality of life for people with GI cancers.

Many people taking part in trials have told us how they’ve appreciated the high standard of care and access to the latest treatments, and very importantly the chance to be an active participant in their own treatment, work with their medical team, and learn more about their cancer and its treatment.

Sarah McGoram (pictured with husband Tom) has survived far beyond expectations, almost twenty years beyond a diagnosis of Gastro-Intestinal Stromal Tumour (GIST) that gave her eighteen months to live.

“The trials gave me access to drugs I wouldn’t otherwise have had access to”, says Sarah.

“And better information. The support from the medical team was invaluable — I was apprehensive at first but they explained clearly the pros and cons. It took a lot of pressure off and gave me a tremendous sense of hope.”

And Tom adds: “The more you engage with a science-based approach to treatment, the more you understand about your own condition and have opportunities to get the drug or treatment you need to help manage it.”

Dr Peter Grimison, a medical oncologist who collaborates with the AGITG on several trials, agrees: “Clinical trials are an extremely important way to make medical progress in cancer, particularly for rare cancers which are difficult to treat.

“Making trials available to my patients allows them access to new treatments that could be life-saving, but are otherwise unavailable or unaffordable.”

Even people whose prognosis is very poor can find comfort in being able to help others.

“People are sitting in front of me who are dying and we don’t have anything to help them”, says Dr Lorraine Chantrill, Principal Investigator on AGITG’s IMPACT trial on pancreatic cancer.

“When we tell them ‘I don’t have a new treatment but I do have an investigational trial – do you want to participate and help future patients?’ they jump at the opportunity.”

Among other achievements, AGITG clinical trials have improved life expectancy for people with gastro-intestinal stromal tumour (GIST) by over 500%, and those with select pancreatic cancer types by 30%. Clinical Trials have proven that for people with oesophageal cancer, adding chemotherapy and radiation therapy before surgery significantly improves survival rates; and identified a specific gene likely to respond to a particular type of chemotherapy, which means improving the treatment for bowel cancer.

If you have a GI cancer (or are supporting someone who does), ask your doctor about whether there might be an AGITG clinical trial suitable for you.

You can also help the AGITG continue its research and clinical trials by donating here today.